Divi's Laboratories 경영진
경영진 기준 점검 3/4
Divi's Laboratories CEO는 Kiran Divi, Jan2020 에 임명되었습니다 의 임기는 6.58 년입니다. 총 연간 보상은 ₹348.40M, 2.6% 급여 및 97.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 ₹446.85B 가치에 해당하는 회사 주식의 20.34% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.2 년과 9.1 년입니다.
핵심 정보
Kiran Divi
최고경영자
₹348.4m
총 보수
| CEO 급여 비율 | 2.64% |
| CEO 재임 기간 | 6.6yrs |
| CEO 지분 보유율 | 20.3% |
| 경영진 평균 재임 기간 | 5.2yrs |
| 이사회 평균 재임 기간 | 9.1yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.분석 기사 • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...내러티브 업데이트 • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
내러티브 업데이트 • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
내러티브 업데이트 • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.내러티브 업데이트 • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.내러티브 업데이트 • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).분석 기사 • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...내러티브 업데이트 • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.내러티브 업데이트 • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).내러티브 업데이트 • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).내러티브 업데이트 • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).내러티브 업데이트 • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).분석 기사 • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...내러티브 업데이트 • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).내러티브 업데이트 • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).분석 기사 • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).분석 기사 • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...분석 기사 • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...내러티브 업데이트 • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.분석 기사 • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...내러티브 업데이트 • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.분석 기사 • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...
새로운 내러티브 • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | ₹29b |
| Mar 31 2026 | ₹348m | ₹9m | ₹26b |
| Dec 31 2025 | n/a | n/a | ₹25b |
| Sep 30 2025 | n/a | n/a | ₹25b |
| Jun 30 2025 | n/a | n/a | ₹23b |
| Mar 31 2025 | ₹308m | ₹9m | ₹22b |
| Dec 31 2024 | n/a | n/a | ₹21b |
| Sep 30 2024 | n/a | n/a | ₹18b |
| Jun 30 2024 | n/a | n/a | ₹17b |
| Mar 31 2024 | ₹228m | ₹9m | ₹16b |
| Dec 31 2023 | n/a | n/a | ₹14b |
| Sep 30 2023 | n/a | n/a | ₹13b |
| Jun 30 2023 | n/a | n/a | ₹15b |
| Mar 31 2023 | ₹248m | ₹9m | ₹18b |
| Dec 31 2022 | n/a | n/a | ₹24b |
| Sep 30 2022 | n/a | n/a | ₹30b |
| Jun 30 2022 | n/a | n/a | ₹31b |
| Mar 31 2022 | ₹377m | ₹5m | ₹30b |
| Dec 31 2021 | n/a | n/a | ₹26b |
| Sep 30 2021 | n/a | n/a | ₹21b |
| Jun 30 2021 | n/a | n/a | ₹20b |
| Mar 31 2021 | ₹282m | ₹10m | ₹20b |
| Dec 31 2020 | n/a | n/a | ₹19b |
| Sep 30 2020 | n/a | n/a | ₹18b |
| Jun 30 2020 | n/a | n/a | ₹16b |
| Mar 31 2020 | ₹184m | ₹8m | ₹14b |
보상 대 시장: Kiran의 총 보수(USD3.66M)는 Indian 시장에서 비슷한 규모 기업의 평균(USD1.05M)보다 높습니다.
보상과 수익: Kiran의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Kiran Divi (50 yo)
6.6yrs
재임 기간
₹348,400,000
보수
Dr. Kiran Satchandra Divi has been the Chief Executive Officer of Divi's Laboratories Limited since January 4, 2020. Dr. Divi has been an Whole-time Director at Divi's Laboratories Limited since August 10,...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Whole-Time Director | 6.6yrs | ₹348.40m | 20.34% ₹ 446.8b | |
| Executive Director | 31.8yrs | ₹512.00m | 데이터 없음 | |
| MD & Executive Director | no data | ₹1.00b | 2.85% ₹ 62.6b | |
| Whole-Time Director (Manufacturing) | 2.5yrs | ₹32.60m | 0.023% ₹ 496.5m | |
| Whole-time Director | 5.2yrs | ₹347.80m | 20.34% ₹ 446.8b | |
| Chief Financial Officer | 1yr | 데이터 없음 | 데이터 없음 | |
| Chief Information Officer | 1.5yrs | 데이터 없음 | 데이터 없음 | |
| Company Secretary & Compliance Officer | 7.1yrs | ₹3.80m | 데이터 없음 | |
| Vice President of Sales | no data | ₹28.70m | 데이터 없음 | |
| Global Quality Head | no data | ₹14.00m | 데이터 없음 | |
| Chief Technologist - PDSC | no data | ₹23.60m | 0.0052% ₹ 113.4m | |
| Chief Technologist - PDSC | no data | ₹23.60m | 데이터 없음 |
5.2yrs
평균 재임 기간
60.5yo
평균 나이
경험이 풍부한 관리: DIVISLAB의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.2 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Whole-Time Director | 25yrs | ₹348.40m | 20.34% ₹ 446.8b | |
| Executive Director | 31.8yrs | ₹512.00m | 데이터 없음 | |
| MD & Executive Director | 35.8yrs | ₹1.00b | 2.85% ₹ 62.6b | |
| Whole-Time Director (Manufacturing) | 2.5yrs | ₹32.60m | 0.023% ₹ 496.5m | |
| Whole-time Director | 9.2yrs | ₹347.80m | 20.34% ₹ 446.8b | |
| Independent Non-Executive Chairman | 9.2yrs | ₹3.70m | 데이터 없음 | |
| Non-Executive Independent Director | 9.1yrs | ₹3.40m | 데이터 없음 | |
| Non-Executive Independent Director | 7.4yrs | ₹2.90m | 데이터 없음 | |
| Non-Executive Independent Director | 6.6yrs | ₹3.30m | 데이터 없음 | |
| Independent Director | 2.3yrs | ₹2.80m | 데이터 없음 |
9.1yrs
평균 재임 기간
68yo
평균 나이
경험이 풍부한 이사회: DIVISLAB의 이사회는 경험이 있음으로 간주됩니다(평균 재임 9.1 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/07 18:44 |
| 종가 | 2026/08/07 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Divi's Laboratories Limited는 52명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |